Literature DB >> 27367645

Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.

Jeffrey J Tosoian1, Meera Chappidi1, Zhaoyong Feng1, Elizabeth B Humphreys1, Misop Han1, Christian P Pavlovich1, Jonathan I Epstein1, Alan W Partin1, Bruce J Trock1.   

Abstract

OBJECTIVE: To update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past three decades. PATIENTS AND METHODS: From January 2010 to October 2015, 4459 men meeting inclusion criteria underwent RP and pelvic lymphadenectomy for histologically confirmed prostate cancer at the Johns Hopkins Hospital. Preoperative clinical stage, serum prostate-specific antigen (PSA) level, and biopsy Gleason score (i.e. prognostic Grade Group) were used in a polychotomous logistic regression model to predict the probability of pathological outcomes categorised as: organ-confined (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+). Preoperative characteristics and pathological findings in men treated with RP since 1983 were collected and clinical-pathological trends were described.
RESULTS: The median (range) age at surgery was 60 (34-77) years and the median (range) PSA level was 4.9 (0.1-125.0) ng/mL. The observed probabilities of pathological outcomes were: OC disease in 74%, EPE in 20%, SV+ in 4%, and LN+ in 2%. The probability of EPE increased substantially when biopsy Gleason score increased from 6 (Grade Group 1, GG1) to 3 + 4 (GG2), with smaller increases for higher grades. The probability of LN+ was substantially higher for biopsy Gleason score 9-10 (GG5) as compared to lower Gleason scores. Area under the receiver operating characteristic curves for binary logistic models predicting EPE, SV+, and LN+ vs OC were 0.724, 0.856, and 0.918, respectively. The proportion of men treated with biopsy Gleason score ≤6 cancer (GG1) was 47%, representing a substantial decrease from 63% in the previous cohort and 77% in 2000-2005. The proportion of men with OC cancer has remained similar during that time, equalling 73-74% overall. The proportions of men with SV+ (4.1% from 3.4%) and LN+ (2.3% from 1.4%) increased relative to the preceding era for the first time since the Partin Tables were introduced in 1993.
CONCLUSIONS: The Partin Tables remain a straightforward and accurate approach for projecting pathological outcomes based on readily available clinical data. Acknowledging these data are derived from a tertiary care referral centre, the proportion of men with OC disease has remained stable since 2000, despite a substantial decline in the proportion of men with biopsy Gleason score 6 (GG1). This is consistent with the notion that many men with Gleason score 6 (GG1) disease were over treated in previous eras.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; PSA; clinical stage; pathological stage; prostate biopsy; prostatectomy

Mesh:

Substances:

Year:  2016        PMID: 27367645     DOI: 10.1111/bju.13573

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

1.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

2.  Nomogram for preoperative prediction of nodal extracapsular extension or positive surgical margins in oropharyngeal squamous cell carcinoma.

Authors:  Mohammad K Hararah; William A Stokes; Bernard L Jones; Ayman Oweida; Ding Ding; Jessica McDermott; Julie Goddard; Sana D Karam
Journal:  Oral Oncol       Date:  2018-06-13       Impact factor: 5.337

3.  Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.

Authors:  Adrien N Bernstein; Jonathan E Shoag; Ron Golan; Joshua A Halpern; Edward M Schaeffer; Wei-Chun Hsu; Paul L Nguyen; Art Sedrakyan; Ronald C Chen; Scott E Eggener; Jim C Hu
Journal:  J Urol       Date:  2017-12-26       Impact factor: 7.450

4.  Stochastic Modeling of Temporal Enhanced Ultrasound: Impact of Temporal Properties on Prostate Cancer Characterization.

Authors:  Layan Nahlawi; Caroline Goncalves; Farhad Imani; Mena Gaed; Jose A Gomez; Madeleine Moussa; Eli Gibson; Aaron Fenster; Aaron Ward; Purang Abolmaesumi; Hagit Shatkay; Parvin Mousavi
Journal:  IEEE Trans Biomed Eng       Date:  2017-11-27       Impact factor: 4.538

5.  Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer.

Authors:  Hailang Liu; Kun Tang; Ding Xia; Xinguang Wang; Wei Zhu; Liang Wang; Weimin Yang; Ejun Peng; Zhiqiang Chen
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

6.  68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.

Authors:  Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Niels J Rupp; Martin Huellner; Michael Messerli; Jan Hendrik Rüschoff; Edwin E G W Ter Voert; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-14       Impact factor: 9.236

7.  Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer.

Authors:  Hailong Liu; Jie Ding; Yanyuan Wu; Di Wu; Jun Qi
Journal:  Cancer Manag Res       Date:  2020-06-15       Impact factor: 3.989

8.  Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a radiologic learning curve.

Authors:  B H E Jansen; F H K Oudshoorn; A M Tijans; M J Yska; A P Lont; E R P Collette; J A Nieuwenhuijzen; A N Vis
Journal:  World J Urol       Date:  2018-04-21       Impact factor: 4.226

9.  Porphyrins are increased in the faeces of patients with prostate cancer: a case-control study.

Authors:  Daniel Riani Gotardelo; Lilia Coronato Courrol; Maria Helena Bellini; Flávia Rodrigues de Oliveira Silva; Carlos Roberto Jorge Soares
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

10.  A signal-on built in-marker electrochemical aptasensor for human prostate-specific antigen based on a hairbrush-like gold nanostructure.

Authors:  Naghmeh Sattarahmady; Amid Rahi; Hossein Heli
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.